Document is current
Any future updates will be listed below
-
Authors
van Leer, B. https://orcid.org/0000-0002-6597-205X
Londema, M.
Kasalak, Ö.
van Snick, J. H.
Duiverman, M. L.
Kuijvenhoven, J. C.
de Kruif, M. D.
Oprea-Lager, D. E.
Pabst, K.
Hellemons, M. E.
Boersma, H. H.
Prokop, M.
Nijsten, M. W.
Glaudemans, A. W. J. M.
Pillay, J.
Slart, R. H. J. A.
,
Beijers, R. J. H. C. G.
van Kuijk, S. M. J.
Gach, D.
Schalekamp, S.
van den Borst, B.
Bek, L. M.
Stöger, J. L.
Beenen, L. F. M.
Lammertsma, A. A.
Postma, D. F.
Mohamed Hoesein, F. A. A.
Gietema, H. A.
Schols, A.
-
Funding
Funding for this research was provided by:
ZonMW (50-56300-98-2104)
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 20 May 2025
First Online: 21 June 2025
Declarations
:
: The study protocol was approved by the Institution Review Board of the University Medical Center Groningen (202100802) and registered at ClinicalTrials.gov (NCT05981885). The study was performed in accordance with the Declaration of Helsinki. All patients provided written informed consent.
: Janesh Pillay is supported by a research grant from the Netherlands Organization for Health Research and Development, The Netherlands (ZonMw Clinical Fellowship grant 09032212110044) and has received funding from ‘a Partnership of Siemens and UMCG for building the future of Health’ (PUSH MO24.00027). The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Riemer Slart is an associate editor for EJNMMI. Information regarding FAPI-46 precursor composition used in this study containing approximately 20% of the non-binding (R)-enantiomer was provided by GE HealthCare and incorporated in this manuscript.
